Faeth Therapeutics, Inc. (FTH) — Cash Flow-to-Debt Ratio
Faeth Therapeutics, Inc. (FTH) has a Cash Flow-to-Debt Ratio of -0.96x as of June 2026, meaning its operating cash flow of $-15.67 Million could theoretically repay -1% of its total liabilities ($16.35 Million) in one year. See FTH FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Faeth Therapeutics, Inc. Cash Flow-to-Debt Ratio (2018–2025)
Historical debt coverage capacity for Faeth Therapeutics, Inc. across 8 annual periods. See FTH equity to assets ratio to measure how much of total assets are equity-financed.
Annual Cash Flow-to-Debt Ratio for Faeth Therapeutics, Inc. (2018–2025)
Year-by-year debt coverage analysis for Faeth Therapeutics, Inc.. For the full cash flow conversion analysis, see Faeth Therapeutics, Inc. cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.75x | $-20.45 Million | $4.31 Million | ▼ -34.2% |
| 2024 | -3.54x | $-24.67 Million | $6.97 Million | ▼ -4.7% |
| 2023 | -3.38x | $-32.02 Million | $9.48 Million | ▼ -29.6% |
| 2022 | -2.61x | $-39.03 Million | $14.97 Million | ▲ +42.2% |
| 2021 | -4.51x | $-30.26 Million | $6.71 Million | ▼ -40.9% |
| 2020 | -3.20x | $-17.70 Million | $5.54 Million | ▼ -2507.9% |
| 2019 | -0.12x | $-8.57 Million | $69.88 Million | ▲ +34.2% |
| 2018 | -0.19x | $-10.31 Million | $55.33 Million | — |